XOMA 3AB, a Novel Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase 1 Clinical Testing May 03, 2011 8:46am EDT
XOMA to Announce First Quarter 2011 Financial Results and Host Webcast Conference Call on May 5 May 03, 2011 7:00am EDT
XOMA Announces Presentation and Webcast at BioCentury Future Leaders Conference Apr 11, 2011 8:00am EDT
XOMA 052 Phase 2b Top Line Results: Glucose Control Not Demonstrated, Positive Anti-inflammatory Effect, Cardiovascular Biomarker and Lipid Improvement and Safety Confirmed Mar 22, 2011 4:20pm EDT
XOMA to Announce 2010 Fourth Quarter Financial Results and Host Conference Call on March 10 Mar 04, 2011 4:02pm EST
Interim Three Month Data From Ongoing Six Month XOMA 052 Phase 2a Trial Support Safety and Biological Activity Jan 06, 2011 4:59pm EST
